Immune checkpoint inhibitors in non-small cell lung cancer

Oncologist

Volumn 22, Issue 1, 2017, Pages 81-88

  Herzberg, Benjamin ^a   Campo, Meghan J ^a   Gainor, Justin F ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Checkpoint inhibition; Cytotoxic T lymphocyte associated antigen 4; Immune therapy; Lung cancer; Non small cell lung cancer; Programmed cell death protein 1 inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; ATEZOLIZUMAB; AVELUMAB; BMS 936559; CARBOPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DOCETAXEL; DURVALUMAB; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; CTLA4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; TAXOID; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; GENE EXPRESSION; HUMAN; KNOCKOUT MOUSE; MELANOMA; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); T LYMPHOCYTE ACTIVATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TAXOIDS;

EID: 85011344685     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2016-0189     Document Type: Article

References (61)

1. McCarthy EF. The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J 2006;26:154-158.
2. Mellman I, Coukos G, Dranoff G. Cancer immu-notherapy comes of age. Nature 2011;480:480-489.
3. Coley WB. II. Contribution to the knowledge of sarcoma. Ann Surg 1891;14:199-220.
4. Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116.
5. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: Early results of a randomised con-trolled trial. Lancet 1999;353:14-17.
6. Topalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti-PD-1 anti-body in cancer. N Engl J Med 2012;366:2443-2454.
7. Prado-Garcia H, Romero-Garcia S, Aguilar-Cazares D et al. Tumor-induced CD8 1 T-cell dysfunc-tion in lung cancer patients. Clin Dev Immunol 2012; 2012:741741.
8. Brahmer J, Reckamp KL, Baas P et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123-135.
9. Borghaei H, Paz-Ares L, Horn L et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015; 373:1627-1639.
10. Finn OJ. Immuno-oncology: Understanding the function and dysfunction of the immune system in cancer. Ann Oncol 2012;23(suppl 8):viii6-viii9.
11. Brahmer JR, Pardoll DM. Immune checkpoint inhibitors: Making immunotherapy a reality for the treatment of lung cancer. Cancer Immunol Res 2013; 1:85-91.
12. Pardoll DM. The blockade of immune check-points in cancer immunotherapy. Nat Rev Cancer 2012;12:252-264.
13. Fife BT, Bluestone JA. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-Checkpoint Inhibitors in NSCL and PD-1 pathways. Immunol Rev 2008;224: 166-182.
14. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-1982.
15. Greenwald RJ, Freeman GJ, Sharpe AH. The B7 family revisited. Annu Rev Immunol 2005;23:515-548.
16. Brunet JF, Denizot F, Luciani MF et al. A new member of the immunoglobulin superfamily— CTLA-4. Nature 1987;328:267-270.
17. Linsley PS, Brady W, Urnes M et al. CTLA-4 is a second receptor for the B cell activation antigen B7. J Exp Med 1991;174:561-569.
18. Walunas TL, Lenschow DJ, Bakker CY et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity 1994;1:405-413.
19. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med 1996;183:2541-2550.
20. Wing K, Onishi Y, Prieto-Martin P et al. CTLA-4 control over Foxp31 regulatory T cell function. Sci-ence 2008;322:271-275.
21. Peggs KS, Quezada SA, Chambers CA et al. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J Exp Med 2009; 206:1717-1725.
22. Sharpe AH, Abbas AK. T-cell costimulation— Biology, therapeutic potential, and challenges. N Engl J Med 2006;355:973-975.
23. Tivol EA, Borriello F, Schweitzer AN et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a criti-cal negative regulatory role of CTLA-4. Immunity 1995;3:541-547.
24. Waterhouse P, Penninger JM, Timms E et al. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 1995;270: 985-988.
25. Leach DR, Krummel MF, Allison JP. Enhance-ment of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736.
26. Agata Y, Kawasaki A, Nishimura H et al. Expres-sion of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int Immunol 1996;8: 765-772.
27. Blank C, Brown I, Peterson AC et al. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD81 T cells. Cancer Res 2004;64:1140-1145.
28. Freeman GJ, Long AJ, Iwai Y et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lym-phocyte activation. J Exp Med 2000;192: 1027-1034.
29. Dong H, Strome SE, Salomao DR et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002;8:793-800.
30. Keir ME, Butte MJ, Freeman GJ et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704.
31. Ahmadzadeh M, Johnson LA, Heemskerk B et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are func-tionally impaired. Blood 2009;114:1537-1544.
32. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol 2008;8:467-477.
33. Konishi J, Yamazaki K, Azuma M et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res 2004; 10: 5094-5100.
34. Nishimura H, Nose M, Hiai H et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999;11: 141-151.
35. Nishimura H, Okazaki T, Tanaka Y et al. Auto-immune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001;291: 319-322.
36. Robert C, Thomas L, Bondarenko I et al. Ipilimu-mab plus dacarbazine for previously untreated meta-static melanoma. N Engl J Med 2011; 364:2517-2526.
37. Hodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363: 711-723.
38. Zatloukal P, Heo D, Park K et al. Randomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2009;27(suppl 15):8071a.
39. Lynch TJ, Bondarenko I, Luft A et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double blind, multicenter phase II study. J Clin Oncol 2012; 30:2046-2054.
40. Wang C, Thudium KB, Han M et al. In vitro char-acterization of the anti-PD-1 antibody nivolu-mab, BMS-936558, and in vivo toxicology in nonhuman primates. Cancer Immunol Res 2014;2: 846-856.
41. Gettinger SN, Horn L, Gandhi L et al. Overall survival and long-term safety of nivolumab (anti-programmed death 1 antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33: 2004-2012.
42. Milne CP, Bryan C, Garafalo S et al. Comple-mentary versus companion diagnostics: Apples and oranges. Biomarkers Med 2015;9:25-34.
43. Garon EB, Rizvi NA, Hui R et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018-2028.
44. Herbst RS, Baas P, Kim DW et al. Pembrolizu-mab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet 2016;387:1540-1550.
45. Herbst RS, Soria JC, Kowanetz M et al. Predic-tive correlates of response to the anti-PD-L1 anti-body MPDL3280A in cancer patients. Nature 2014; 515:563-567.
46. Fehrenbacher L, Spira A, Ballinger M et al. Ate-zolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POP-LAR): A multicentre, open-label, phase 2 randomised controlled trial. Lancet 2016;387:1837-1846.
47. Rizvi NA, Brahmer JR, Ou SI et al. Safety and clinical activity of MEDI4736, an anti programmed celldeath-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). J Clin Oncol 2015;33(suppl):8032a.
48. Hellmann MD, Friedman CF, Wolchok JD. Com-binatorial cancer immunotherapies. Adv Immunol 2016;130:251-277.
49. Curran MA, Montalvo W, Yagita H et al. PD-1 and CTLA-4 combination blockade expands infiltrat-ing T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010;107:4275-4280.
50. Larkin J, Chiarion-Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monother-apy in untreated melanoma. N Engl J Med 2015; 373:23-34.
51. Antonia SJ, Gettinger SN, Chow LQM et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: Interim phase I results. J Clin Oncol 2014;32(suppl):5s, 8023a.
52. Hellmann MD, Gettinger SN, Goldman JW. CheckMate 012: Safety and efficacy of first-line (1L) nivolumab (nivo; N) and ipilimumab (ipi; I) in advanced (adv) NSCLC. J Clin Oncol 2016;34(suppl): 3001a.
53. Antonia S, Goldberg SB, Balmanoukian A et al. Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: A mul-ticentre, phase 1b study. Lancet Oncol 2016;17: 299-308.
54. Antonia S, Ou S, Khleif S et al. Clinical activity and safety of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small-cell lung cancer. Ann Oncol 2014;25(suppl 4):426-470.
55. Garon E, Gandhi L, Rizvi N et al. Antitumor activity of pembrolizumab (Pembro; MK-3475) and correlation with programmed death ligand 1(PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC). Ann Oncol 2014;25:1-41.
56. Kerr K, Tsao M, Nicholson A et al. Programmed death-ligand 1 immunohistochemistry in lung can-cer: In what state is this art? J Thorac Oncol 2015;10: 985-989.
57. Gainor JF, Shaw AT, Sequist LV et al. EGFR muta-tions and ALK rearrangements are associated with low response rates to PD-1 pathway blockade in non-small cell lung cancer (NSCLC): A retrospective analy-sis. Clin Cancer Res 2016 [E-pub ahead of print].
58. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology: Mutational landscape determines sen-sitivity to PD-1 blockade in non-small cell lung can-cer. Science 2015;348:124-128.
59. Tumeh PC, Harview CL, Yearley JH et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014;515:568-571.
60. Hugo W, Zaretsky JM, Sun L et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 2016;165: 35-44.
61. Ribas A, Hodi FS, Callahan M et al. Hepatotoxic-ity with combination of vemurafenib and ipilimu-mab. N Engl J Med 2013;368:1365-1366.